Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | BRAF V600E MAP2K1 P124L |
Therapy | PLX4720 + Selumetinib |
Indication/Tumor Type | melanoma |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
BRAF V600E MAP2K1 P124L | melanoma | sensitive | PLX4720 + Selumetinib | Preclinical | Actionable | In a preclinical study, combined treatment with Koselugo (selumetinib) and PLX4720 inhibited growth of melanoma cells harboring BRAF V600E and expressing MAP2K1 P124L in culture (PMID: 19915144). | 19915144 |
PubMed Id | Reference Title | Details |
---|---|---|
(19915144) | MEK1 mutations confer resistance to MEK and B-RAF inhibition. | Full reference... |